Fungal peritonitis in peritoneal dialysis patients: is previous antibiotic therapy an essential condition? by Guimarães Rosa, Nuno et al.
Fungal peritonitis in peritoneal dialysis patients: is previous antibiotic
therapy an essential condition?
Nuno Guimarães Rosa,1 Sónia Silva,2 José António Lopes,2 Patrı́cia Branco,2 Edgar de Almeida,2
Carlos Ribeiro,3 Fernando Abreu,2 José Barbas2 and M. Martins Prata2
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Summary The aim of this study was to analyse the clinical and microbiological features of fungal
peritonitis, in chronic peritoneal dialysis patients, focusing on non-traditional risk
factors for this feared complication. From 2001 to 2004, five episodes of fungal
peritonitis were diagnosed in five different patients, accounting for 4.5% of all
peritonitis cases seen during this period. Candida spp. were the most frequent isolates. In
all cases, peritoneal dialysis catheter removal and switching to haemodialysis were
necessary. In these five cases of fungal peritonitis only one was preceded by antibiotic
use, within the previous 3 months, the classical risk factor for fungal peritonitis.
Identifying predisposing factors usually not taken into account, may lead to an early
diagnosis and to a better understanding of fungal peritonitis pathogenesis.
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Introduction
Fungal peritonitis is a rare but serious complication of
chronic peritoneal dialysis, responsible for 2.6–14.3% of
peritonitis occurring in this set of patients.1–5 Fungal
peritonitis has been traditionally associated with high
morbidity and mortality,6,7 often leading to technique
failure. Clinical presentation of fungal peritonitis is
similar to bacterial peritonitis and Candida spp. is the
most common isolate accounting for 70–89.3% of
cases.1,2,5,6 Previous antibiotic therapy is the most
common risk factor associated to fungal peritonitis.1,2,5
The approach to fungal peritonitis has changed
considerably in the last few years. In ISPD guidelines
2000,8 fungal peritonitis was not considered a clear
indication for catheter removal. More recent recom-
mendations,7 however, have stressed the importance of
early peritoneal catheter removal in association with
antifungal therapy, a procedure that has improved
patients outcome. Another important aspect of fungal
peritonitis management relates to determining antifun-
gal sensitivities as imidazole resistant strains have been
emerging.7 In order to highlight the importance of other
fungal peritonitis risk factors, besides previous antibiotic
therapy, we report five cases of fungal peritonitis that
occurred in our Unit, four of which unrelated to this
established risk factor.
Patients and methods
Between January 2001 and June 2004, a total of 95
patients with chronic kidney disease underwent perito-
neal dialysis in our Unit. Fifty-seven (60%) patients were
on automated peritoneal dialysis and 38 (40%) on
continuous ambulatory peritoneal dialysis. Peritoneal
dialysis access was achieved with a Tenckhoff peritoneal
catheter inserted by laparoscopy.
We reviewed the clinical records of the five patients
who had fungal peritonitis during this period. Fungal
peritonitis diagnosis was made based on clinical and
laboratorial features such as fever, abdominal pain,
cloudy dialysate, leucocyte count in dialysate higher
than 100 mm)3 with >50% of neutrophils and a positive
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fungus culture in one or more occasions8 (ISPD Guide-
lines, 2000). Culture of peritoneal dialysate was per-
formed by inoculation of 10 ml of peritoneal effluent into
a blood culture medium (BacT/Alert), that was incuba-
ted for 7 days at 37 C in an aerobic environment and by
concentration of 40 ml of peritoneal effluent followed by
inoculation of the sediment on solid and liquid culture
media (Blood agar, MacConkey agar, Sabouraud agar,
Todd Hewitt broth and Beef infusion). These media were
incubated for 48 h at 37 C in aerobiosis. For the
isolation of fungi the incubation time of Sabouraud’s
agar was prolonged for a minimum of 7 days at room
temperature. Identification of yeast was made using the
Walkaway System with apropriate panels for automated
identification (Microscan Rapid Yeast ID; Dade Behring
Inc., West Sacramento, CA, USA). Antifungal sensitivity
tests were not available in our institution.
Results
In the aforementioned period, a total of 105 episodes of
bacterial peritonitis and 5 (4.5%) episodes of fungal
peritonitis, one per patient, were recorded. The inci-
dence of fungal peritonitis was 0.03 fungal peritonitis/
patient/year. The isolates were Candida parapsilosis (two
cases), Candida guilliermondii, Candida albicans and Rho-
dotorula rubra (one case each).
The patients were three men and two women with a
mean age of 48 years (31–69). Mean time on peritoneal
dialysis was 44.8 months (4–66). Chronic kidney dis-
ease aetiology was diabetic nephropathy in three
patients, lupus nephritis in one patient and chronic
glomerulonephritis in another.
All patients had abdominal pain and all, but one had a
cloudy dialysate. Other clinical signs included vomiting,
diarrhoea and peritoneal irritation. Three patients had
ileus and two developed intra-abdominal abscess. Mean
dialysate white cell count was 440 ± 200 cells mm)3
with 82% ± 10.1% neutrophils. Only one patient had
fungaemia (Candida albicans). Fungal peritonitis risk
factors were identified in all patients (Table 1); only one
patient had received antibiotherapy in the previous
month for bacterial peritonitis.
All patients initiated antifungal therapy with an
azole antifungal; oral fluconazole (three patients) or
intra-peritoneal fluconazole (two patients) followed, in
absence of clinical improvement, by oral itraconazole
(one patient) and intravenous amphotericin B (all cases).
Because of poor clinical response, all peritoneal catheters
had to be removed within the first week of antifungal
therapy. Peritoneal catheter tips were not cultured.
In all cases, patients were switched to haemodialysis
and none resumed peritoneal dialysis. One patient died
30 days after institution of antifungal therapy. She was
a diabetic and suffered a fatal ischemic stroke.
Discussion
The prevalence of fungal peritonitis in our Unit was
similar to that found in other series (2.6–14.3%).
Candida spp. contributed to 70–89.3%1,2,5,6 of fungal
peritonitis episodes in different studies. In our series
Candida spp. were responsible for 80% of fungal perito-
nitis episodes. Rhodotorula rubra, a rare but documented
agent of fungal peritonitis,9 was isolated in one patient.
Mortality rate is variable but can be as high as
53.6%,5 particularly, if catheter removal is delayed by
>24 h.6 The concern that prolonging peritoneal dialysis
catheter in situ might be associated with higher
mortality rate is reflected by the new ISPD Recommen-
dations,7 in which fungal peritonitis is now a formal
indication for immediate catheter removal. In all
patients fungal peritonitis determined peritoneal dialysis
dropout, which is in agreement with previous reports
stating fungal peritonitis as an important cause of
technique failure.6
Only one patient had previous antibiotic therapy,
within the 3 months preceding the fungal peritonitis
episode. This is traditionally considered as the classic
risk factor for fungal peritonitis in peritoneal dialysis
Table 1 Risk factors for fungal peritonitis.
Risk factors









Patient 1 Candida parapsilosis 4
Patient 2 Candida parapsilosis 4 4
Patient 3 Candida guilliermondii 4 4 4
Patient 4 Candida albicans 4
Patient 5 Rhodotorula rubra 4
*within the previous 3 months preceding the fungal peritonitis.
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patients. In fact, previous antibiotic therapy is the main
predisposing clinical condition for fungal peritonitis,
preceding 28.6–87.3% of fungal peritonitis epi-
sodes.1,2,5,10 In our patients, after reviewing literature,
we were able to identify other less known fungal
peritonitis risk factors: diabetes mellitus (three patients);
systemic lupus erythematosus (one patient); use of
steroids (one patient) and multiple episodes of bacterial
peritonitis >3 months before fungal peritonitis episode
(two patients). In two patients, we were able to identify
more than one risk factor for fungal peritonitis.11,12
Diabetes mellitus was identified in 29–64.3% of the
patients in different fungal peritonitis series.5,10,11 In
our cohort, 60% of the patients were diabetic. In a
retrospective study of 20 fungal peritonitis episodes,12
lupus patients had a higher incidence of fungal perito-
nitis and five in six patients with lupus were on steroids
during fungal peritonitis episode. Patients with previous
bacterial peritonitis developed fungal peritonitis more
commonly 10 and the frequent occurrence of the former
was identified as a fungal peritonitis risk factor.12
Environmental sources of fungus were not studied
because the fungal peritonitis were episodic and
involved different fungus species.
Conclusions
We highlight that the absence of previous antibiotic
therapy, in a peritoneal dialysis patient with a clinical
suspicion of peritonitis, does not exclude fungus origin
and should prompt the search for other less frequent risk
factors such as diabetes mellitus, systemic lupus erithe-
matosus, use of steroids and previous multiple episodes
of bacterial peritonitis.
References
1 Goldie SJ, Kiernan-Tridle L, Torres C, Gorban-Brennan N,
Dunne D, Kliger AS, Finkelstein FO. Fungal peritonitis in a
large chronic peritoneal dialysis population: a report of 55
episodes. Am J Kidney Dis 1996; 28: 86–91.
2 Chan TM, Chan CY, Cheng SW, Lo WK, Lo CY, Cheng IK.
Treatment of fungal peritonitis complicating continuous
ambulatory peritoneal dialysis with oral fluconazole: a
series of 21 patients. Nephrol Dial Transplant 1994; 9:
539–42.
3 Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A,
Harding G. Analysis of microbiological trends in peritoneal
dialysis-related peritonitis from 1991 to 1998. Am J Kid-
ney Dis 2000; 36: 1009–13.
4 Manzano-Gayosso P, Hernandez-Hernandez F, Mendez-
Tovar LJ, Gonzalez-Monroy J, Lopez-Martinez R. Fungal
peritonitis in 15 patients on continuous ambulatory
peritoneal dialysis (CAPD). Mycoses 2003; 46: 425–9.
5 Prasad KN, Prasad N, Gupta A, Sharma RK, Verma AK,
Ayyagari A. Fungal peritonitis in patients on continuous
ambulatory peritoneal dialysis: a single centre Indian
experience. J Infect 2004; 48: 96–101.
6 Wang AY, Yu AW, Li PK, Lam PK, Leung CB, Lai KN, Lui
SF. Factors predicting outcome of fungal peritonitis in
peritoneal dialysis: analysis of a 9-year experience of
fungal peritonitis in a single center. Am J Kidney Dis 2000;
36: 1183–92.
7 Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A,
Holmes C, Kuijper EJ, Tao Li PK, Lye WC, Mujais S,
Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L.
ISPD guidelines/recommendations. Peritoneal dialysis-
related infections: 2005 update. Perit Dial Int 2005; 25:
107–131.
8 Keane W, Bailie G, Boeschoten E, Gokal R, Golper T,
Holmes C, Kawaguchi Y, Piraino B, Riella M, Vas S. ISPD
guidelines/recommendations. Adult peritoneal dialysis-
related peritonitis treatment recommendations: 2000
update. Perit Dial Int 2000; 20: 396–411.
9 Eisenberg ES, Alpert BE, Weiss RA, Mittman N, Soeiro
R. Rhodotorula rubra peritonitis in patients undergoing
continuous ambulatory peritoneal dialysis. Am J Med
1983; 75: 349–52.
10 Wong PN, Mak SK, Lo KY, Tong GM, Wong AK. A ret-
rospective study of seven cases of Candida parapsilosis
peritonitis in CAPD patients: the therapeutic implications.
Perit Dial Int 2000; 20: 76–9.
11 Kleinpeter MA, Butt AA. Non Candida albicans fungal
peritonitis in continuous ambulatory peritoneal dialysis
patients. Adv Perit Dial 2001; 17: 176–9.
12 Huang JW, Hung KY, Wu KD, Peng YS, Tsai TJ, Hsieh BS.
Clinical features of and risk factors for fungal peritonitis in
peritoneal dialysis patients. J Formos Med Assoc 2000; 99:
544–8.
Fungal peritonitis
 2006 The Authors
Journal Compilation  2006 Blackwell Publishing Ltd • Mycoses, 50, 79–81 81
